Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.75 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18855748 | 0.98 | NPC1 (0.71) | NPC1SIGMAR1CYP1A2MCHR1EPHX1 | |
| SCHEMBL22861414 | 0.89 | NPC1 (0.59) | NPC1SIGMAR1CYP1A2EPHX1GAA | |
| SCHEMBL13939521 | 0.84 | NPC1 (0.88) | NPC1CYP1A2MCHR1 | |
| SCHEMBL16016535 | 0.84 | NPC1 (0.88) | NPC1CYP1A2MCHR1 | |
| SCHEMBL13086520 | 0.84 | NPC1 (0.52) | NPC1SIGMAR1CYP1A2MCHR1EPHX2 | |
| SCHEMBL13993536 | 0.82 | NPC1 (0.50) | NPC1SIGMAR1CYP1A2MCHR1GAA | |
| SCHEMBL16678890 | 0.82 | NPC1 (0.50) | NPC1SIGMAR1CYP1A2MCHR1EPHX2 | |
| SCHEMBL8263002 | 0.82 | NPC1 (0.50) | NPC1SIGMAR1CYP1A2MCHR1GAA | |
| SCHEMBL79064 | 0.82 | NPC1 (0.50) | NPC1SIGMAR1CYP1A2MCHR1EPHX2 | |
| Hydrochloric Acid SCHEMBL15352413 | 0.81 | NPC1 (0.49) | NPC1MCHR1EPHX2KEAP1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240358634-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-10-31 | — | — | US | disclosed |
| US-11969501-B2 | Auris formulations for treating otic diseases and conditions | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-04-30 | — | — | US | disclosed |
| US-11918653-B2 | Triglyceride otic formulations and uses thereof | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-03-05 | — | — | US | disclosed |
| US-20220040095-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2022-02-10 | — | — | US | disclosed |
| EP-0195624-B1 | FLUORESCENT LABELS AND LABELED SPECIES AND THEIR USE IN ANALYTICAL ELEMENTS AND DETERMINATIONS | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1992-08-19 | — | — | EP | disclosed |
| US-4801504-A | IMMUNOASSAY | EASTMAN KODAK COMPANY (US) | 1989-01-31 | — | — | US | disclosed |
| US-4719182-A | COMPLEXING POLYSACCUARIDES, REACTIVE SPECIES, ADDITION POLYMERS; IMMUNOASSAYS; RARE EARTH CHELATES | EASTMAN KODAK COMPANY (US) | 1988-01-12 | — | — | US | disclosed |
| US-4666461-A | Fuel treatment compositions | THE LUBRIZOL CORPORATION (US) | 1987-05-19 | — | — | US | disclosed |
| EP-0085510-A2 | Compositions for use in alcohol and alcohol containing fuels | The Lubrizol Corporation (US) | 1983-08-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11918653-B2 | Triglyceride otic formulations and uses thereof | CETP, LIPA, APOB | NPC1 22/4885SIGMAR1 3104/4885CYP1A2 3053/4885 |
| US-20240358634-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | NPC1 189/4885SIGMAR1 4652/4885CYP1A2 3771/4885 |
| US-20220040095-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | NPC1 189/4885SIGMAR1 4652/4885CYP1A2 3771/4885 |
| US-11969501-B2 | Auris formulations for treating otic diseases and conditions | OTC, AQP4, SLC26A4 | NPC1 189/4885SIGMAR1 4652/4885CYP1A2 3771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.